Bailey Hilty Chu

Dr. Bailey Hilty Chu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Surgical Education
Verified
Journal Article
Closed access
CLCasey R. Lamb
Casey R. Lamb
RSRobert D. Shaw
Robert D. Shaw
BCBailey Hilty Chu
Bailey Hilty Chu
SWSandra L. Wong
Sandra L. Wong
KRKari M. Rosenkranz
Kari M. Rosenkranz

1 August 2024 in Hepatology Communications
Verified
Journal Article
Open access
PBPaul R. Burchard
Paul R. Burchard
LRLuis I. Ruffolo
Luis I. Ruffolo
NUNicholas A. Ullman
Nicholas A. Ullman
BDBenjamin S. Dale
Benjamin S. Dale
YDYatee A. Dave
Yatee A. Dave
RHRoberto Hernandez-Alejandro
Roberto Hernandez-Alejandro
Background: Cholangiocarcinoma (CCA) features highly desmoplastic stroma that promotes structural and functional resistance to therapy. Lysyl oxidases (LOX, LOXL1–4) catalyze collagen cross-linking, thereby increasing stromal rigidity and facilitating therapeutic resistance. Here, we evaluate the role of lysyl oxidases in stromal desmoplasia and the effects of pan-lysyl oxidase (pan-LOX) inhibition in CCA. Methods: Resected CCA and normal liver specimens were analyzed from archival tissues. Spontaneous and orthotopic murine models of intrahepatic CCA (iCCA) were used to assess the impact of the pan-LOX inhibitor PXS-5505 in treatment and correlative studies. The functional role of pan-LOX inhibition was interrogated through in vivo and ex vivo assays. Results: All 5 lysyl oxidases are upregulated in CCA and reduced lysyl oxidase expression is correlated with an improved prognosis in resected patients with CCA. Spontaneous and orthotopic murine models of intrahepatic cholangiocarcinoma upregulate all 5 lysyl oxidase isoforms. Pan-LOX inhibition reversed mechanical compression of tumor vasculature, resulting in improved chemotherapeutic penetrance and cytotoxic efficacy. The combination of chemotherapy with pan-LOX inhibition increased damage-associated molecular pattern release, which was associated with improved antitumor T-cell responses. Pan-LOX inhibition downregulated macrophage invasive signatures in vitro, rendering tumor-associated macrophages more susceptible to chemotherapy. Mice bearing orthotopic and spontaneously occurring intrahepatic cholangiocarcinoma tumors exhibited delayed tumor growth and improved survival following a combination of pan-LOX inhibition with chemotherapy. Conclusions: CCA upregulates all 5 lysyl oxidase isoforms, and pan-LOX inhibition reverses tumor-induced mechanical forces associated with chemotherapy resistance to improve chemotherapeutic efficacy and reprogram antitumor immune responses. Thus, combination therapy with pan-LOX inhibition represents an innovative therapeutic strategy in CCA. Export

8 September 2025 in Annals of Surgery Open
Verified
Journal Article
Open access
BCBailey Hilty Chu
Bailey Hilty Chu
ALAnthony Loria
Anthony Loria
TDTotadri Dhimal
Totadri Dhimal
LRLydia Rafferty
Lydia Rafferty
MJMarie Jacobs
Marie Jacobs
FFFergal Fleming
Fergal Fleming
Objective: To evaluate patient-reported outcomes (PROs) in rectal cancer patients who underwent neoadjuvant therapy followed by watch-and-wait. Background: Advancements in rectal cancer therapies have improved oncologic outcomes and increased focus on long-term treatment effects. Watch-and-wait, which aims for organ preservation in patients with a clinical complete response to neoadjuvant therapy, is used more frequently. While watch-and-wait may reduce functional impairments associated with proctectomy, its association with PROs is poorly understood. Methods: We performed a systematic review and meta-analysis of studies reporting PROs for patients with stage I–III rectal adenocarcinoma treated with neoadjuvant therapy and watch-and-wait. Random-effects model meta-analysis was performed when feasible; otherwise, data were synthesized through a narrative review. Results: Twenty-five studies (3139 patients) reported PROs for patients receiving neoadjuvant therapy followed by watch-and-wait (n = 1283), proctectomy (n = 1583), local excision (n = 263), or declined surgery (n = 10). Most studies (64.0%) excluded patients with local regrowth, leaving PRO data for 103 such patients. Fourteen studies compared PROs between treatment groups after neoadjuvant therapy. Meta-analyses demonstrated fewer bowel symptoms and improved quality of life (QoL) in 1/6 subscales for watch-and-wait. Across 24 QoL comparisons, 14 showed improvement in some subscales for watch-and-wait, while 10 found no difference. For 24 symptom scale comparisons, 11 indicated some improvement with watch-and-wait, and 13 found no differences between groups. Conclusions: Watch-and-wait offers the potential to avoid permanent ostomy and surgical morbidity. However, more robust data are needed to assess its association with PROs compared to proctectomy or local excision. Researchers should prioritize publishing QoL data to better inform shared decision-making.

2 December 2024 in JAMA Network Open
Verified
Journal Article
Open access
BCBailey Hilty Chu
Bailey Hilty Chu
ALAnthony Loria
Anthony Loria
TDTotadri Dhimal
Totadri Dhimal
XCXueya Cai
Xueya Cai
SGShan Gao
Shan Gao
FFFergal J. Fleming
Fergal J. Fleming
Importance: Close surveillance for detection of local tumor regrowth is critical for patients opting for nonoperative management after neoadjuvant therapy for rectal cancer. However, there are minimal data regarding the feasibility and adherence to National Comprehensive Cancer Network (NCCN) surveillance guidelines for these patients.Objective: To determine adherence rates to NCCN-recommended surveillance in patients undergoing nonoperative management for rectal cancer.Design, Setting, and Participants: This retrospective cohort study included patients treated at a single academic center (University of Rochester, Rochester, New York) from 2012 to 2023, with analysis completed from March through May 2024. Patients with clinical stage I to III rectal cancer who underwent treatment with neoadjuvant therapy, achieved a clinical complete response (or initially near complete clinical response), and elected for nonoperative management were enrolled.Exposure: Achievement of recommended surveillance.Main Outcomes and Measures: The primary outcome was adherence to surveillance guidelines for patients undergoing nonoperative management for rectal cancer. Secondary outcomes included assessment of oncologic outcomes stratified by adherence to surveillance.Results: Eighty-five patients (54 male [63.5%]; median [IQR] age, 63.0 [54.0-73.0] years) were managed nonoperatively and followed for a median of 4.04 years (95% CI, 3.17-4.58 years). The 5-year overall survival was 82.3% (95% CI, 71.8%-94.5%), the 5-year disease-specific survival was 95.1% (95% CI, 89.6%-100.0%), the rate of local regrowth was 24.7% (21 patients), and the rate of distant metastases was 12.9% (11 patients). Among the 77 patients with more than 6 months of follow-up in their first year of surveillance, only 39.0% of patients (30 patients) achieved NCCN-recommended surveillance in the first year, and this decreased to 15.0% (3 patients) by year 5. However, the time to local regrowth and distant metastasis were similar regardless of the level of surveillance.Conclusions and Relevance: In this cohort study of patients with rectal cancer undergoing surveillance after nonoperative management, most did not achieve NCCN-recommended guidelines, although outcomes were not associated with surveillance intensity. This highlights the need for prospective evaluation of a surveillance regimen that is both feasible for patients and health care systems increasingly using nonoperative management. In addition, studies are warranted to explore patient preferences in rectal cancer care and to identify barriers to optimal surveillance.

15 August 2024 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
BCBailey Hilty Chu
Bailey Hilty Chu
ALAnthony Loria
Anthony Loria
TDTotadri Dhimal
Totadri Dhimal
YLYue Li
Yue Li
FCFernando Colugnati
Fernando Colugnati
FFFergal J. Fleming
Fergal J. Fleming

26 August 2024 in Surgery
Verified
Journal Article
Closed access
BCBailey Hilty Chu
Bailey Hilty Chu
ALAnthony Loria
Anthony Loria
XCXueya Cai
Xueya Cai
SGShan Gao
Shan Gao
TDTotadri Dhimal
Totadri Dhimal
FFFergal J. Fleming
Fergal J. Fleming